Table 3.
Encapsulated exosomes in efficient chemo drug delivery.
| Drug | Exosome source | Cell line/animal model | Loading method | Result | Year | Ref. |
|---|---|---|---|---|---|---|
| Gemcitabine monophosphate (GEMP) and paclitaxel | BM-MSCs | 1) MiaPaca-2 cells 2) 3D tumor spheroids 3) Nude mice |
Electroporation | 1) ↑ Endocellular dose of GEMP 2) ↑ Uptake of GEM, especially GEMP 3) ↑ Therapeutic efficacy 4) ↓ Cancer proliferative activity and chemoresistance |
2020 | (174) |
| Oxaliplatin | BM-MSCs | 1) PANC-02 cells 2) C57BL/6 mice |
Electroporation | 1) ↑ Cellular uptake efficiency 2) ↑ Cytotoxicity and immunogenic cell death response 3) ↑ In vivo antitumor efficacy and enhanced immunity |
2021 | (175) |
| Gemcitabine | BM-MSCs | CFPAC-1 cells | Priming of MSCs | 1) ↓ Cancer-related cell proliferation by 70% to 80% 2) Inhibit HUVEC proliferation |
2015 | (176) |
| Gemcitabine and deferasirox | M1 macrophage | 1) PANC-1 cells 2) 3D tumor spheroids |
Electroporation | 1) ↑ Iron removal efficacy 2) Reverse drug resistance 3) ↑ hENT1 expression for the transport of drug combinations into cells 4) ↑ Accumulation of chemotherapeutic agents in the cytosol 5 ) ↓ Invasiveness of GEM resistance |
2021 | (177) |
| Curcumin | 1) PANC-1 2) MIA PaCa-2 |
1) PANC-1 2 ) MIA PaCa-2 |
Methanol sonication | ↓ Pancreatic adenocarcinoma cell viability | 2015 | (178) |